Microbot Medical (MBOT) Downgraded by Zacks Investment Research
Zacks Investment Research lowered shares of Microbot Medical (NASDAQ:MBOT) from a hold rating to a sell rating in a report published on Saturday.
According to Zacks, “Microbot Medical Inc. is engaged in the research, design, development and commercialization of micro-robotics assisted medical technologies. Its product candidate includes the Self Cleaning Shunt for the treatment of hydrocephalus and Normal Pressure Hydrocephalus and TipCAT, a self-propelling, semi-disposable endoscope which is being developed initially for use in colonoscopy procedures. Microbot Medical Inc., formerly known as Stemcells, Inc., is headquartered in Hingham, MA. “
Separately, ValuEngine raised shares of Microbot Medical from a hold rating to a buy rating in a report on Thursday, September 6th.
Microbot Medical (NASDAQ:MBOT) last released its earnings results on Tuesday, August 14th. The biotechnology company reported ($0.04) EPS for the quarter, hitting analysts’ consensus estimates of ($0.04). research analysts expect that Microbot Medical will post -2.4 earnings per share for the current fiscal year.
About Microbot Medical
Microbot Medical Inc, a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob and TipCAT micro-robotic technologies, is developing two product candidates, including the Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; and a self-propelling, semi-disposable endoscope, which is used in colonoscopy procedures.
See Also: How to Invest in Growth Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.